术前VI-RADS 5分可靠识别膀胱尿路上皮癌膀胱外侵犯并预测延迟膀胱切除术时间
本研究回顾性分析149例接受根治性膀胱切除术的肌层浸润性膀胱癌患者,评估VI-RADS 5分预测膀胱外病变(≥pT3)的准确性及对延迟膀胱切除术时间的影响。结果显示VI-RADS 5分敏感度90.2%、特异度98.1%,曲线下面积94.2%,且独立增加延迟膀胱切除术风险(OR 2.81)。提示高VI-RADS评分或可避免深部TURBT,改用采样TURBT。
要点
- VI-RADS 5分预测膀胱外侵犯敏感度90.2%、特异度98.1%。
- VI-RADS 5分独立增加延迟膀胱切除术风险(OR 2.81)。
- 高VI-RADS评分或可避免深部TURBT,改用采样TURBT。
核心结论
- VI-RADS在TURBT前能有效区分膀胱外病变与肌层局限膀胱癌。
- VI-RADS 5分独立预测膀胱切除术时间显著延迟。
- 未来高VI-RADS评分或可避免广泛原发切除的并发症,改用采样TURBT获取组织学。
研究设计与样本
- 回顾性研究纳入149例T2-T4a、cN0-M0的肌层浸润性膀胱癌患者。
- 患者为不适合或拒绝顺铂联合新辅助化疗者,术前接受膀胱mpMRI、分期TURBT后行根治性膀胱切除术。
- VI-RADS 5分39例,VI-RADS 2-4分110例。
主要发现
- VI-RADS 5分检测膀胱外病变的敏感度90.2%(95%CI 84-94.3)、特异度98.1%(95%CI 94-99.6)。
- 阳性预测值94.9%(95%CI 89.6-97.6),阴性预测值96.4%(95%CI 91.6-98.6)。
- 曲线下面积94.2%(95%CI 88.7-99.7),读者间一致性极好(Κinter 0.89)。
- VI-RADS 5分与2-4分的平均(SD)膀胱切除术时间分别为4.2(2.3)和2.8(1.1)个月(P < 0.001)。
- VI-RADS 5分独立增加延迟膀胱切除术风险(比值比2.81,95%CI 1.20-6.62)。
临床怎么用
- 术前mpMRI检测VI-RADS 5分可帮助识别膀胱外病变,辅助制定手术策略。
- 对VI-RADS 5分患者,可考虑避免深部TURBT,改用采样TURBT获取组织学以降低并发症。
- 需关注VI-RADS 5分患者膀胱切除术时间延迟风险,优化治疗流程。
局限性
- 回顾性研究设计。
- 样本量有限且单中心。
- 需进一步前瞻性、更大规模、多机构试验验证临床适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: (I) To determine Vesical Imaging-Reporting and Data System (VI-RADS) score 5 accuracy in predicting locally advanced bladder cancer (BCa), so as to potentially identify those patients who could avoid the morbidity of deep transurethral resection of bladder tumour (TURBT) in favour of histological sampling-TUR prior to radical cystectomy (RC). (II) To explore the predictive value of VI-RADS score 5 on time-to-cystectomy (TTC) outcomes. PATIENTS AND METHODS: We retrospectively reviewed patients' ineligible or refusing cisplatin-based combination neoadjuvant chemotherapy who underwent multiparametric magnetic resonance imaging (mpMRI) of the bladder prior to staging TURBT followed by RC for muscle-invasive BCa. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) were calculated for VI-RADS score 5 vs. score 2-4 cases to assess the accuracy of mpMRI for extravesical BCa detection (≥pT3). VI-RADS score performance was assessed by receiver operating characteristics curve analysis. A Κ statistic was calculated to estimate mpMRI and pathological diagnostic agreement. The risk of delayed TTC (i.e. time from initial BCa diagnosis of >3 months) was assessed using multivariable logistic regression model. RESULTS: A total of 149 T2-T4a, cN0-M0 patients (VI-RADS score 5, n = 39 vs VI-RADS score 2-4, n = 110) were examined. VI-RADS score 5 demonstrated sensitivity, specificity, PPV and NPV, in detecting extravesical disease of 90.2% (95% confidence interval [CI] 84-94.3), 98.1% (95% CI 94-99.6), 94.9% (95% CI 89.6-97.6) and 96.4% (95% CI 91.6-98.6), respectively. The area under the curve was 94.2% (95% CI 88.7-99.7) and inter-reader agreement was excellent (Κinter 0.89). The mean (SD) TTC was 4.2 (2.3) and 2.8 (1.1) months for score 5 vs 2-4, respectively (P < 0.001). VI-RADS score 5 was found to independently increase risk of delayed TTC (odds ratio 2.81, 95% CI 1.20-6.62). CONCLUSION: The VI-RADS is valid and reliable in differentiating patients with extravesical disease from those with muscle-confined BCa before TURBT. Detection of VI-RADS score 5 was found to predict significant delay in TTC independently from other clinicopathological features. In the future, higher VI-RADS scores could potentially avoid the morbidity of extensive primary resections in favour of sampling-TUR for histology. Further prospective, larger, and multi-institutional trials are required to validate clinical applicability of our findings.
引用
- Del Giudice F, Leonardo C, Simone G, et al. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease? BJU Int. 2020. PMID: 32783347. doi:10.1111/bju.15188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。